[ Price : $8.95]
AbbVie says a pivotal Phase 3 (TEMPO-1) trial for tavapadon in early Parkinsons disease met its primary and secondary endpoints.[ Price : $8.95]
Federal Register notice: FDA proposes to reclassify qualitative hepatitis B virus (HBV) antigen assays, qualitative and quantitati...[ Price : $8.95]
Four Ropes & Gray attorneys identify the key provisions in three new FDA clinical trial modernization guidances.[ Price : $8.95]
Federal Register notice: FDA determines for patent extension purposes the regulatory review period for SpringWorks Therapeutics Og...[ Price : $8.95]
Pfizer withdraws its sickle cell disease drug Oxbryta from all approved markets after data show the overall benefit does not outwe...[ Price : $8.95]
Three stakeholder organizations make comments and suggestions for changes in an FDA draft guidance on diversity action plans to in...[ Price : $8.95]
FDA lifts a clinical hold on Biomea Fusions Phase 1-2 clinical trials of its investigational covalent menin inhibitor BMF-219 in T...[ Price : $8.95]
Investigative journalists write in BMJ about FDA advisory committee members financial conflicts of interest in the consideration o...